(SeaPRwire) - NASA 的望遠鏡發現了一顆此前未知的圍繞天王星運行的衛星。 NASA 週二宣布了這項發現，並補充說這顆衛星於2月2日首次被發現。科學家們估計，這顆新發現的衛星直徑約為六英里。據NASA稱，它「微小」的尺寸可能是其他望遠鏡——以及近四十年前進行飛越的航海家2號太空船——此前未曾發現它的原因。相比之下，地球的平均直徑超過2,000英里，而天王星最大的衛星提坦妮亞，直徑約為1,000英里。 「這是一顆小衛星，但卻是個重要的發現，」Southwest Research Institute太陽系科學與探索部門的首席科學家瑪麗亞姆·埃爾·穆塔米德在NASA的聲明中表示。 在這項發現之前，天王星——距離太陽第七顆行星——已知擁有27顆衛星。該行星的衛星常被稱為「文學衛星」，因為它們都以威廉·莎士比亞和亞歷山大·蒲柏作品中的人物命名。該行星有五顆主要衛星：米蘭達、艾瑞爾、溫布里爾、提坦妮亞和奧伯隆。 這顆新衛星使天王星已知衛星總數達到29顆，目前被指定為S/2025 U1，但尚未有官方名稱。據NASA稱，該名稱需要由負責命名和指定天文物體的國際天文學聯合會批准。該太空機構補充說，這項發現尚未經過同行評審過程。 今年之前，最近發現的衛星是於2023年11月發現的S/2023 U1。 SETI Institute研究團隊成員馬修·蒂斯卡雷諾在NASA的聲明中表示，這項最新發現「很可能意味著圍繞天王星運行的衛星還有更多複雜性有待發現」。 「很可能還有更多這樣的衛星，我們只需要繼續尋找，」蒂斯卡雷諾告訴《時代》雜誌。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
國務院已撤銷逾6,000份學生簽證
(SeaPRwire) - 美國國務院表示，自1月以來，已撤銷6,000多份學生簽證，因為川普政府對國際學生及其他赴美移民採取了措施。 美國國務院發言人表示，約三分之二的學生簽證因逾期居留及其他涉嫌違法行為而被取消，包括襲擊、酒駕和入室盜竊。他們說，大約200至300份簽證因「支持恐怖主義」而被撤銷，依據的是，該法條禁止從事或被認為可能從事「恐怖活動」的外國出生人士入境美國。 這些撤銷行動最初由報導。 川普政府已將國際學生和學生簽證計劃作為其重塑美國高等教育和移民的更廣泛努力的一部分。擁有合法身份但無公民身份的學生，若參與了親巴勒斯坦抗議活動，包括那些在大學校園內搭建營地或以其他方式表達對巴勒斯坦支持的人，一直是政府特別關注的對象。其中幾人，包括前Columbia University研究生Mahmoud Khalil和Tufts University博士生Rümeysa Öztürk，被Immigration and Customs Enforcement (ICE)逮捕，一名官員在Khalil被捕後提及總統關於反猶太主義的行政命令。其他人也受到了調查。 外國出生的學生也成為聯邦政府與Harvard University之爭的焦點，該大學拒絕讓步於政府要求，包括改變其多元、平等和包容實踐，以及改變其招聘政策以納入更多保守聲音。在期間，政府試圖撤銷該大學招收國際學生的能力、停止其聯邦研究撥款和資金等等。大學官員與政府之間的一項協議目前正在談判中。 政府的其他措施則更廣泛地針對外國出生的學生。 ，數千名國際學生的移民記錄從一個信息系統中被刪除，許多情況是因輕微或已撤銷的違法行為——暫時使他們在美國失去合法身份——直到政府在學生和法院系統的大規模公眾壓力下於當月晚些時候撤銷了該行動。 幾週後，美國國務院於6月表示，新的學生簽證申請人必須將其社交媒體帳戶設為「公開」，以便審查可能存在的「對我國公民、文化、政府、機構或立國原則的敵意」。 6月的公告稱：「美國簽證是一種特權，而非權利。每項簽證裁決都是國家安全決定。美國在簽證簽發過程中必須保持警惕，以確保申請入境美國的人不打算傷害美國人民和我們的國家利益。」本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
FDA 警告民眾勿食用可能具放射性蝦子
(SeaPRwire) -本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。 FDA 針對在 Walmart 銷售的某些冷凍蝦產品發出警告，因為這些產品可能受到放射性同位素銫-137 的污染。
新鴻基公司公佈2025中期業績
EQS 新聞 via SeaPRwire.com / 2025-08-21 / 09:00 UTC+8 投資管理表現強勁復甦 帶動淨利潤激增逾10倍至8.87億港元 新鴻基有限公司（香港股份代號：86）（「新鴻基公司」或「公司」，連同其附屬公司「集團」）公佈截至2025年6月30日止之止六個月業績，業績表現錄得顯著改善。 財務摘要 截至下列日期止六個月 截至 2024年 12月止年度 （百萬港元） 2025年 6月 2024年 6月 變動 總收益 2,799.9 1,951.5 43.5% 4,262.3 除稅前溢利 1,087.4 307.4 253.7% 861.3 公司股東應佔溢利 887.0 75.4 1,076.4% 377.7 每股基本盈利（港仙） 45.3 3.9 1,061.5% 19.3 中期股息（港仙） 12.0 12.0 - 14.0* 每股賬面值（港元） 11.2 10.7 4.7% 10.8 * 第二次中期股息 2025年上半年，集團的另類投資平台各核心業務均表現理想，帶動集團整體表現強勁。其中，投資管理業務的表現尤其亮眼並實現了顯著的復甦，其多元化投資組合的回報全面提升。面對充滿挑戰的經濟環境，集團的信貸業務表現依然穩健，並持續作出堅實貢獻。同時，基金管理平台延續強勁的增長勢頭，其資產管理規模^（「AUM」）錄得顯著擴張。這些整體成果彰顯了集團戰略轉型的成功，旗下多元化互補平台正日益產生協同效應，並提升長遠股東價值。 集團期內錄得除稅前溢利10.874億港元（2024年上半年：3.074億港元）。公司股東應佔溢利上升逾10倍至8.87億港元（2024年上半年：7,540萬港元）。此強勁復甦主要受投資管理業務帶動；隨著市場對中國相關資產的情緒轉趨樂觀，該業務把握了有利的退出窗口，在實現多項投資退出的同時，亦錄得可觀的估值收益。每股基本盈利為45.3港仙（2024年上半年：3.9港仙）。 公司董事會宣派截至2025年6月30日止六個月之中期股息每股12港仙，與去年同期維持不變。 期內，公司回購了總值1,240萬美元（2024年上半年：2,780萬美元）的中期票據。計及銀行及其他借貸總額的減少，淨負債比率由2024年底的31.2%進一步降至29.6%。截止2025年6月30日，集團的每股賬面值為11.2港元，較2024年底（10.8港元）及2024年6月30日（10.7港元）分別增加3.7%及4.7%。 分項表現 截至下例日期止六個月的除稅前貢獻 於下例日期的分項資產 （百萬港元） 2025年 6月 2024 年 6月 變動 2025年 6月 2024 年 12月 信貸業務 消費金融 374.6 400.3 -6.4% 17,468.8 17,761.5 按揭貸款 9.5 25.0 -62.0% 1,734.6 2,155.6 小計 384.1 425.3 -9.7% 19,203.4 19,917.1 投資管理# 785.6 (147.5) N/A 16,182.0 14,914.2 基金管理 (5.0) 1.3 N/A 22.3 59.6 集團管理及支援# (77.3) 28.3 N/A 2,246.2 2,409.2 總計 1,087.4 307.4 253.7% 37,653.9 37,300.1 # 已重列2024 年上半年，原因是公司自2025 年1 月1 日起停止集團管理及支援向投資管理收取內部資金成本，並根據其各自的平均資產結餘分配該兩個分項的融資成本。該重列亦包括對外匯對沖工具的收益或虧損重新分組，以符合相應的投資資產分類。 投資管理 投資管理業務錄得投資收益9.979億港元，平均資產回報率達6.4%。幾乎所有資產類別均有貢獻，其中私募股權佔最大比重，收益為5.829億港元，主要受惠於投資項目估值上升，以及期內成功實現多項投資退出。期內，集團的兩項直接及跟投項目 — Jefferson Capital (納斯達克證券代碼: JCAP) 及聖貝拉（2508.HK）— 分別於美國及香港成功上市。企業持股錄得強勁反彈，產生了3.035億港元的收益，主要由於公司對中國相關持股進行戰略配置，而此配置受益於投資者情緒的持續改善。對沖基金組合在市場持續不明朗的情況下保持防禦姿態，實現穩健回報。得益於新冠病毒疫情期間共同投資的旅遊相關項目的持續復甦，以及債務投資的強勁利息收入，特殊機會投資及結構信貸業務錄得 4.5% 的增長。 基金管理 基金管理分部錄得強勁增長，其資產管理規模^（「AUM」）於2025年6月30日創下歷史新高，達25.5億美元（2024年：20.18億美元）。此增長得益於公司基金合作夥伴關係、家族辦公室方案及SHKCP基金共同錄得4.34億美元的淨現金流入及1.55億美元的市場收益。隨著資產管理規模的組成持續變動，其中的公司資產負債表資本已下降至 15.0%（2024 年： 20.1%），而外部投資者資本已增加至 85.0%（2024年： 79.9%），反映了市場對公司另類投資管理平台平台的認可度不斷提升。 值得注意的是，公司其中一個基金夥伴ActusRayPartners，在歐洲、亞洲及日本採用股票市場中性策略，其AUM增長至超過17億美元。由公司內部團隊管理的全球對沖基金母基金策略SHK Latitude Alpha Fund，亦錄得穩健增長。ActusRayPartners和SHK Latitude Alpha Fund均憑藉其卓越的絕對回報和夏普比率，雙雙入圍2025年HFM亞太區表現大獎的最終提名名單。公司亦完成了一項對Wentworth Capital類似的成長型資本投資，為其新債務投資業務線提供資金。 新鴻基公司的家族辦公室解決方案（「FOS」）是一個多家族辦公室平台 ，為家族辦公室及超高淨值人士提供獨特的另類投資機會，並於期內繼續擴大其客戶群及AUM。FOS讓公司的客戶能夠透過機構級別的投資實現投資組合多元化，同時追求具有吸引力的風險調整回報。該平台的成長反映了目前市場對精緻化財富管理解決方案的需求日益增長，同時亦彰顯公司的投資團隊成功甄選了優質的投資機會。 戰略合作夥伴關係 期內，新鴻基公司與Mubadala Investment Company旗下的資產管理公司Mubadala Capital建立了戰略合作夥伴關係。該戰略夥伴關係結合 Mubadala 在全球私募市場的專業知識和公司在大中華區的深厚根基，為客戶打造一個獲得頂級主權財富基金及共同投資機會的強大平台。公司與 GAM Investments (「GAM」) 的夥伴關係在其戰略轉型及提升投資能力計劃中取得穩步進展。公司進一步推進合作關係，讓公司的基金產品能夠接觸 GAM 已建立的歐洲分銷網絡，開闢全新業務增長途徑，包括與公司的內部普通合夥人產生協同效應。 信貸業務 信貸業務錄得除稅前溢利3.841億港元。消費金融業務方面，公司新的SIM信用卡自推出以來，累計交易額達24億港元，期內交易量按年增長超過60%。面對物業市場下滑，按揭貸款業務 — 新鴻基信貸對批出新貸款採取審慎態度。自去年推出向機構擁有的按揭組合提供端對端樓按資產管理服務以來，新鴻基信貸於去年11月獲委任為一個價值1億美元的住宅按揭組合的服務商。今年6月，新鴻基信貸再獲委任為另一個價值7,000萬美元的住宅按揭組合的服務商。該兩個組合均由新鴻基公司與機構資本合作，從發展商收購。該等發展商均有意剝離由資產負債表撥資的按揭組合，並將其管理和服務外判給信賴的第三方供應商。 集團執行主席李成煌先生表示：「展望2025年下半年，我們預期市場環境將充滿挑戰，當中包括環球不確定因素以及地緣政治緊張局勢的影響。這些因素將繼續為資產價值及整體宏觀經濟帶來壓力。 儘管面對這些挑戰，我們仍保持審慎樂觀。我們將繼續聚焦於資本效益、嚴謹的風險管理及營運的靈活性，這是我們保持韌性的關鍵。維持穩健的資產負債表及充裕的流動性始終是我們的重點優先事項，使我們能夠在市場動盪時期進行投資並把握機遇。我們的多元化互補平台在完成戰略轉型後日益產生協同效應，推動經常性收入增長，並提升長遠股東價值 。」 如欲了解更多2025年中期業績的詳細資料, 請參閱業績公佈。 ^ 「資產管理規模」（「AUM」）指所管理、諮詢、分銷或以其他方式提供服務的資產總值，包括： 1. 由SHKCP基金合作夥伴管理的資產，主要與早期另類投資管理人合作成立，合作模式靈活， 視乎其進入市場的準備程度而定； 2. 由SHKCP 管理的資產，包括由SHKCP 及家族辦公室解決方案管理的基金，以及由SHKCP 提供諮詢及╱或交易安排的資產； 3. 新鴻基公司擁有股權，並由新鴻基公司的戰略聯盟管理的經擁有權調整資產；及 4. SHKCP為第三方管理人分銷的資產。 新鴻基公司釐定資產管理規模的方法反映了新鴻基公司不同的業務線，乃基於新鴻基公司在資產中的經濟權益及╱或新鴻基公司控制權的重要性。其與新鴻基公司就監管申報計算資產管理規模的方法不同。 - 完 - 關於新鴻基有限公司 新鴻基有限公司 (香港股份代號:86) (「新鴻基公司」/「公司」，連同其附屬公司「集團」) 是一家領先的香港金融機構，在另類投資和財富管理領域備受肯定。新鴻基公司成立於1969年，其多元化的投資組合，涵蓋公開市場、信貸和另類投資策略(其中包括房地產和私募股權)，締造長期經風險調整回報。 憑藉其紮根亞洲的傳承，新鴻基公司支持和培育該地區優秀且具專業能力的新晉資產管理公司，賦能他們實現卓越表現。集團亦利用其長久以來建立的投資業務專長和豐富資源，透過其家族辦公室解決方案，為理念一致的合作伙伴和超高淨值投資者提供量身定制的投資解決方案。截至2025年6月30日，集團的資產總值約為377億港元。 有關新鴻基公司更多的資訊，請瀏覽 www.shkco.com或關注公司領英。 媒體查詢，請聯絡： 博雅集團 冷書杰 +852 5443 4320 梁家立 +852 9190 1969 詹子悅 +852 9142 2528 電郵：SHKCo@hkstrategies.com 2025-08-21 此財經新聞稿由EQS Group via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php
Rust Mobile首次封閉測試定於11月開啟
深圳, 2025年8月20日 - (亞太商訊 via SeaPRwire.com) - 在本月早些時候備受期待的全球首秀之後，Level Infinite 將於11月初開啟《Rust Mobile》首次封閉測試。玩家們可以在 2025 年 8 月 20 日至 24 日於科隆舉辦的 gamescom 上，率先親身體驗這款遊戲。《Rust Mobile》將經典的開放世界生存玩法完整呈現，並針對行動裝置進行了優化，讓數百萬粉絲熟悉並熱愛的體驗隨時隨地都能上手。本作由 Facepunch Studios 官方授權，在忠實還原原作精神的同時，也為行動端帶來全新的生存方式。從收集資源、建造堅固基地，到殘酷的 PvP 戰鬥，以及伴隨信任與背叛而來的緊張氛圍，行動版完整呈現了《Rust》的核心精髓。玩家不僅能夠在 gamescom 上率先感受遊戲的魅力，還可透過即將到來的封閉測試進一步體驗其獨特樂趣。《Rust Mobile》亮相 2025 科隆遊戲展參展觀眾可前往 06.1 展館 - C-051G 展位，在這裡親身體驗遊戲，並參與一系列將《Rust》世界帶入現實的特色活動。活動包括與主題道具互動、沉浸式感受展位環境等。每位參與者都將獲得一次轉動「戰利品轉盤」的機會，有機會贏取 2025 科隆遊戲展獨家紀念品，包括限量版海報和環保袋。首次封閉測試將於今年11月開啟《Rust Mobile》首次封閉測試將於 2025 年 11 月初上線，屆時將邀請來自北美、西歐及部分亞洲地區的 30,000 名玩家參與。本次測試將提供四種語言版本：英語、日語、繁體中文和泰語，並支援 iOS、Android 及平板裝置，確保玩家能夠在自己熟悉的平台上暢玩遊戲。封閉測試現已開放註冊，玩家可前往 www.rustmobile.com 報名。欲了解更多有關《Rust Mobile》的資訊或進行預註冊，請訪問 rustmobile.com，或關注遊戲的 X 帳號與 YouTube 頻道。有關科隆遊戲展開館時間，請訪問 www.gamescom.global 。關於 Level InfiniteLevel Infinite 是騰訊旗下的全球遊戲品牌，致力於隨時隨地為全球玩家帶來引人入勝且獨具特色的遊戲體驗。該品牌還為全球範圍內的開發者和合作工作室提供多種服務與資源，幫助他們釋放遊戲潛力。Level Infinite 既是《PUBG MOBILE》《王者榮耀》《勝利女神：NIKKE》等爆款遊戲的發行商，也是《沙丘：覺醒》（Funcom 開發）、《戰鎚40K：Darktide》等眾多遊戲的深度合作夥伴。欲了解更多關於 Level Infinite 的資訊，請訪問 www.levelinfinite.com 。聯絡資訊Kirsty EndfieldSwipe Right PRtencent@swiperight.gg來源: Level Infinite Copyright 2025 亞太商訊 via SeaPRwire.com.
Spritzer Sparkling Adds a Fizzy Twist to Merdeka and Hari Malaysia 2025 with “Kasi Sparkling, Baru Kick!”
A bubbly boost to Malaysians’ favourite drinks, uniting the nation through flavour and funKUALA LUMPUR, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - This Merdeka and Hari Malaysia, Spritzer Sparkling is adding an extra pop to the nation’s celebrations with “Kasi Sparkling, Baru Kick!”. This high-energy campaign is a tribute to Malaysia’s favourite pastime – bonding over hearty food and thirst-quenching drinks. From the eternal “Where to eat?” debates to late-night mamak sessions that stretch into early mornings, these shared moments are part of what makes us Malaysian.Inspired by the lively, welcoming atmosphere of mamak restaurants nationwide – the melting pot where Malaysians of every race, language, and background gather – Spritzer Sparkling is bringing a fun twist to your favourite local beverages with exciting engagement games and prizes to be won at selected mamak outlets, guaranteed to refresh your senses and spark national pride.Mamak Culture, Now with More SparkleFrom teh ‘o’ to sirap limau and asam boi, Malaysian drinks are iconic in their own right. Spritzer Sparkling is taking these familiar flavours and giving them a bubbly boost at some of your favourite neighbourhood mamak restaurants, creating new taste experiences that blend tradition with modern fun.Mamak restaurants have always been the heart of get-togethers for Malaysians from all walks of life; where friends, families, and even strangers share tables, stories, and laughter. This campaign captures that same magic in every sip, celebrating the diversity of our people while proving that great taste knows no boundaries.Photo 1: The three new Spritzer Sparkling drink recipes in the Kasi Sparkling, Baru Kick! CampaignA Campaign Video That is Bursting with EnergyShowcasing the Malaysian spirit, “Kasi Sparkling, Baru Kick!” is a colourful, feel-good celebration video featuring “Aneh”, the friendly mamak waiter. Infused with a twist on our favourite thirst-quenchers, the campaign highlights three mouth-watering drink recipes, each given an irresistible sparkling twist, brought to life by a vibrant local cast speaking different regional dialects, with Aneh delivering the mamak’s urban rhythm in his signature rap style.Watch it now on Spritzer Water YouTube channel and feel the fizz yourself.Photo 2: Kasi Sparkling, Baru Kick! campaign videoJoin the Festivities NationwideFrom Merdeka to Malaysia Day, the celebration will come alive with a sparkling kick at selected mamak chain outlets – including Restoran Nasi Kandar Subaidah, Restoran Hameediyah, and Nasi Kandar Bestari. Enjoy exclusive combo deals featuring the new sparkling drink creations and join exciting roving roadshows designed to surprise, delight, and refresh your taste buds.Whether you are there for the food, the drinks, or the atmosphere, you will not want to miss this limited-time celebration. All event details, locations, and recipes are available at the official campaign page: sparklingmerdeka2025.spritzer.com.mySo, this season, let us raise our glasses to unity, flavour and fizz. Your favourite local drinks are getting a sparkling new twist—Malaysian flavours with extra kick—ready to enjoy at home or at your favourite mamak. Taste the celebration, anywhere you are.About SpritzerEstablished in 1989, Spritzer is Malaysia’s largest producer of bottled water, offering a wide range of products that include natural mineral water, distilled water, sparkling water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.Our water is sourced from deep underground aquifers within 430 acres of pristine rainforest, naturally protected from pollution. It takes over 15 years to filter through ancient rock layers, becoming enriched with essential minerals, particularly silica, which supports collagen formation for healthy skin and strong bones.Spritzer is committed to sustainability and innovation, using 100% recyclable packaging and working toward becoming a fully circular brand by 2030. Our Industry 4.0 facilities and zero-energy automated warehouse demonstrate our dedication to efficiency, environmental care, and forward-thinking growth.For more information, please visit www.spritzer.com.my.For media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2025 ACN Newswire via SeaPRwire.com.
香港小輪公佈 2025 年度中期業績 收益減少 5%
EQS 新聞 via SEAPRWire.com / 2025-08-20 / 09:34 UTC+8 業績摘要 回顧集團收益為港幣 1.99 億元，較去年減少 5%。 截至 2025 年 6 月 30 日止 6 個月期間，股東應佔溢利為港幣 1 億 2,200 萬元，較去年增長 36%。 每股盈利為港幣 34 仙。 宣佈派發截至 2025 年 12 月 31 日止年度之中期股息每股港幣 10 仙。 （2025 年 8 月 21 日 – 香港） – 香港小輪(集團)有限公司（本「公司」，連同附屬公司，總稱本「集團」；香港聯交所股份編號：0050）公佈截至 2025 年 6 月 30 日止 6 個月內之中期業績。業績回顧於回顧期內，集團截至二零二五年六月三十日止六個月基礎溢利為港幣 6,900 萬元，較去年同期減少約19%。計及投資物業公允價值之變動，集團截至 2025 年 6 月 30 日止 6 個月，股東應佔溢利為港幣 1 億2,200 萬元，較 2024 年上半年同期上升約 26%。每股盈利為港幣 34 仙，而去年同期為港幣 25 仙。董事會宣派於截至 2025 年 12 月 31 日止年度之中期股息每股港幣 10 仙（2024 年：中期股息每股港幣10 仙）。中期股息將於 2025 年 9 月 26 日（星期五）派發予於 2025 年 9 月 12 日（星期五）辦公時間結束時名列股東名冊上之股東。地產發展及投資業務於回顧期內，集團之商舖及商場毛租金收入為港幣 6,000 萬元，較去年同期減少 5%。於報告期末，「城中匯」之商舖已全部租出，「亮賢居」及「嘉賢居」之商舖出租率分別為 95%及 91%，而「逸峯廣場」及「港灣豪庭廣場」之出租率分別為 87%及 80%。毛租金收入減少及出租率下降是由於若干租戶未能面對市道疲弱和經營環境困難。集團將調整和優化租賃策略，引入新品牌和營運者，以維持毛租金收入及出租率。「帝御」（屯門青山公路 - 青山灣段 8 號）合營發展項目集團已將售出的 1,748 伙住宅單位交付買家，部份住宅單位則安排出租，以增加集團經常性收益。「映岸」（長沙灣通州街 280 號）重建項目由於本港私人住宅租務市場向好，租金回報率上升，集團已獲市區重建局批准將「映岸」住宅部份轉作青年宿舍用途。該兩幢青年宿舍將會由東華三院營運，並命名為「東華‧南昌匯」，為民政及青年事務局批出在「將酒店和旅館轉作青年宿舍用途的資助計劃」下的第六個項目。集團於本年 6 月底開始收取已約定的市值租金。收購「大鴻輝（荃灣）中心」（荃灣眾安街 55 號）地下A 區商舖 於 2025 年 8 月 19 日，本集團（透過一間全資附屬公司）與一名獨立第三方賣方訂立臨時協議，以代價港幣 260,000,000 元收購位於香港新界荃灣眾安街 55 號「大鴻輝（荃灣）中心」（其為一商業發展項目）地下 A 區的多個商舖（總樓面面積約為 12,720 平方呎）及標牌區（「收購事項」）。該物業的出售將連同現有租約及特許權。於 2025 年 8 月，該物業的每月租金及特許權收入約港幣 1.22 百萬元，按代價港幣 260,000,000 元計算之年度化總租金回報率約為 5.6%。本集團目前擬持有該物業作投資用途。收購事項構成本公司一項須予披露交易，並須遵守《上市規則》第 14 章項下的申報及公告規定。收購事項之完成預定於 2025 年 9 月 30 日或之前進行。有關收購事項之進一步詳情已載於本公司另一份日期為2025 年 8 月 19 日之公告。渡輪、船廠及相關業務於回顧期內，渡輪、船廠及相關業務錄得港幣 1,250 萬元虧損，相對去年同期虧損增加港幣 950 萬元。虧損增加的主要原因為其中一艘渡輪於上半年更換損毀引擎而導致洋紫荊維港遊業務收入減少。集團已經成功向運輸署就北角至觀塘運載危險品車輛的渡輪服務申請加價，新票價已於 2025 年 4 月 12 日生效，有望於下半年減少虧損。醫療、保健及美容服務集團現正在尖沙咀 H Zentre 提供心臟科、外科、骨科、整形外科及泌尿科等專科服務，業績穩步上揚並於回顧期內繼續錄得盈利。集團以「全面醫護」品牌分別於尖沙咀「美麗華廣場」及大角咀「港灣豪庭廣場」設立的脊椎及痛症中心已漸上軌道。香港政府積極提升全民健康，其對於醫療系統的改革措施，也漸趨預防疾病。有見及此，集團透過引入先進醫療儀器，配合專業註冊脊醫及運動訓練師，為痛症患者提供適切療程，有助改善患者健康。為延伸服務並進一步完善給予不同患者在骨科、手術後和各類型受傷後的康復需求，集團亦與一家在香港擁有超過 20 年經驗的專業運動及體適能中心合作，於 H Zentre 設立物理治療中心，為不同患者度身訂造各種專項訓練和康復計劃，預期該中心於本年第三季內開始營運。位於尖沙咀「美麗華廣場」佔地 1 萬 2,000 平方呎面積之 AMOUR 醫美中心，開業以來顧客人數不斷增加，截至 2025 年 6 月 30 日止 6 個月的營業額為港幣 2,200 萬元，與去年同期相比增加 26%。於 2025 年6 月 30 日根據公認會計準則尚未計入回顧期內損益賬之已收取預付套票款項為港幣 1,500 萬元。在迎接開業三週年之際，AMOUR 醫美中心已經在「美麗華廣場」擴展租用面積，利用現有基礎設施創造營運協同效應，為尊貴客戶提供升級體驗，讓集團能提供更廣泛的服務及應對增加的客戶量。回顧期內，集團的保健及美容業務雖未錄得淨利潤，但扣除利息、稅項、折舊及攤銷前的利潤整體已錄得正值。集團會繼續與專科醫生、專科中心以及醫療器材及產品供應商洽商合作，尋求擴充醫療、保健及美容業務。 展望展望下半年，集團預期收益主要來自物業租金及銀行存款利息收入。集團擁有穩定現金流，將針對市場需求調整租賃策略，持續優化租戶組合，同時密切留意物業市場狀況以尋找合適的投資機會。香港小輪總經理李嘉豪先生總結︰「香港小輪集團成立於 1923 年，並由過去單一從事小輪業務，成功轉型為一個綜合性企業。我們在未來的發展中，將繼往開來，與時俱進並因時制宜多元化業務。集團一直堅持不懈地堅守「以民為本」的可持續發展目標，抓緊守護大灣區大健康的機遇，在靈活求變、盡心回饋社會的同時，為股東創造價值。」業績詳情請瀏覽刊登於本公司網站 www.hkf.com 及香港交易所披露易網站 www.hkexnews.hk 之 2025年中期業績公佈。 – 完 – 關於香港小輪(集團)有限公司於 1923 年成立，香港小輪(集團)有限公司主要從事物業發展及投資業務，經營渡輪及船廠營運，醫療、保健及美容服務。若有進一步垂詢，請聯絡徐倩珩電話： (852) 2159 7719傳真： (852) 3568 8941電郵：ir@hkf.com 2025-08-20 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php
冠君產業信託公佈2025年度中期業績
- 朗豪坊商場開業20周年「立足本地，引領全球潮流文化」，成品牌進駐熱點，Chiikawa拉麵首間海外分店掀熱潮- 花園道三號於2025年到期的租約已全部處理，續約率維持在高水平- 朗豪坊辦公樓推出結合六大健康維度「6D Wellness」的創新概念，強化其一站式身心健康及生活時尚總匯的市場定位- 香港銀行同業拆息下降節省利息開支，2025年債務成功全額再融資香港，2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 持有花園道三號及朗豪坊物業的冠君產業信託（股份代號：2778）公布截至 2025 年 6 月 30 日止的中期業績。業績摘要 2025上半年2024上半年變動租金收益總額 （百萬港元）1,0291,115- 7.6%物業收益淨額（百萬港元）859954- 10.0%可分派收入（百萬港元）476544- 12.6% 每基金單位分派（港元）0.07010.0809- 13.3% 於2025年6月30日於2024年12月31日變動物業組合總值（百萬港元）58,09860,104- 3.3%每基金單位資產淨值（港元）6.797.16- 5.2%資產負債比率24.5%23.7%+ 0.8pp概覽2025年上半年，儘管全球經濟因貿易緊張局勢和地緣政治衝突而面對重重阻力，但香港的市場氣氛獲多項利好因素支持。股市回暖、香港銀行同業拆息於第二季回落，住宅銷售趨穩定，以及旅遊業穩步復蘇均有助抗衡外部壓力。然而，港人外遊熱潮未退，消費力外移令本地零售市道受壓。與此同時，寫字樓租賃市場依然淡靜，反映供求持續失衡。在此市況下，本信託的可分派收入下跌12.6%至4.76億港元，而每基金單位分派（「每基金單位分派」）則減少13.3%至0.0701港元。冠君產業信託行政總裁侯迅女士（左），冠君產業信託投資及投資者關係總監陸嘉萍女士（右）花園道三號雖然中環整體寫字樓市場的租賃動力仍然疲弱，但隨着金融市場轉趨活躍，我們接到的租賃查詢有所增加，需求主要來自金融相關企業。花園道三號落實引進一批新的租賃面積較小的租戶，包括家族辦公室；而一名現有銀行業租戶亦於物業內擴充。於2025年6月30日，花園道三號寫字樓的出租率為80.7%。該物業的租金收益期內減少5.4%至5.40億港元（2024年：5.71億港元）。我們持續推動續租工作，2025年到期的租約已全部處理完畢且續約率維持在高水平，當中包括多名主要租戶的續租。而2026年到期的租約亦有超過70%已續租。朗豪坊辦公樓報告期內，朗豪坊辦公樓推出名為「6D Wellness」的YouTube頻道，藉此強化朗豪坊辦公樓作為一站式身心健康及生活時尚總匯的市場定位。於2025年6月30日，在該物業的租戶組合中，生活時尚（身心健康）行業租戶佔比達68%。於2025年6月30日，朗豪坊辦公樓的出租率保持在86.9%的穩定水平。我們擴大了共享工作空間的營運規模並增設「Social Wellness Hall」，專為舉辦工作坊及交流活動而設，正好呼應辦公樓推廣身心健康的定位。市場租金繼續面對挑戰，租金收益因而減少9.1%至1.51億港元（2024年：1.66億港元）。冠君產業信託行政總裁侯迅女士朗豪坊商場今年迎接開業20周年的朗豪坊商場，繼續秉持「Stay Local，Trend Global」（「立足本地，引領全球潮流文化」）的願景。透過沉浸式體驗和限定商品，我們成功吸引破紀錄的人潮及推動銷售，並在八月刷新單日人流紀錄。近日，首次進軍香港的時裝品牌BENLAI，以及全城首家以生活風格為主題的期間限定店Umbro均在朗豪坊商場開業，人氣拉麵店Chiikawa Ramen Buta亦選址朗豪坊商場設立首家海外分店，旋即成為高人氣新熱點。於2025年6月30日，商場的出租率維持在99.2%的高水平，目前屬已承諾悉數租出的狀態。消費行為的改變為租戶帶來挑戰，租金收益跌至3.38億港元（2024年：3.78億港元）。分派本信託期內可分派收入下跌12.6% 至4.76億港元（2024年：5.44億港元），而每基金單位分派則減少13.3%至0.0701港元（2024年：0.0809港元）。按2025年6月30日的基金單位收市價2.08港元計算，相當於年度分派率6.7%。資產值於2025年6月30 日，本信託旗下物業組合的估值為581億港元，較2024年12月31日的601億港元減少3.3%。可持續發展我們繼續透過提升氣候抗禦力、建立有意義的聯繫及促進社區福祉，為我們的生態圈創造共享價值。報告期內，花園道三號引入人工智能製冷機組優化系統，全年節省大廈制冷設備的能源用量達6.1%。我們透過「綠『惜』環保約章」計劃，推動寫字樓和零售租戶攜手實現可量化的環保目標。此外，我們舉辦以「創新．啟發．融合」為主題的「冠君產業信託 ESG Gala」，凝聚逾千名租戶和商業夥伴，共同推進可持續營運及共融舉措。展望儘管香港零售業已重拾增長，金融市場亦見反彈，預料本信託於2025年後續期間的整體經營環境依然嚴峻。雖然港元利率回落有助節省利息支出，但續租租金下跌或將持續壓抑租金收益及令分派較去年為低。面對競爭激烈的市場環境，我們將繼續以靈活的營運策略積極應對。有關冠君產業信託(股份代號：2778)冠君產業信託擁有及投資提供租金收入的寫字樓及零售物業。信託主要投資位於優越地點的甲級商用物業。現時擁有花園道三號及朗豪坊兩幢位於香港的地標性物業，並以合資股權形式擁有位於倫敦市中心的 66 Shoe Lane，總樓面面積約300萬平方呎，讓投資者可直接投資於優質甲級寫字樓及零售物業。信託自2023年榮獲全球房地產GRESB可持續的最高五星級別。冠君產業信託管理人乃鷹君資產管理（冠君）有限公司，為鷹君集團的成員。網站: www.championreit.com Copyright 2025 亞太商訊 via SeaPRwire.com.
盈立集團積極擴張 開設12間分行 紮根香港新加坡 服務全球投資者
香港，2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 由周大福控股戰略入股的uSMART盈立證券欣然宣佈香港落馬洲港鐵站、西九龍高鐵站分行已正式投入服務，涵蓋陸路出入境和高鐵樞紐客戶群。為隆重其事，盈立證券今日在西九龍分行舉行簡單而隆重的開幕儀式，並邀得不少財經界精英出席，令活動生色不少。開幕禮上，盈立證券執行董事李建翰先生 (Neo Lee) 表示：「為提供更便捷的金融服務予區內居民，盈立集團計劃年內於香港及新加坡兩地社區內開設分行，連同總部客戶專區，服務點增至12個，進駐尖沙咀、銅鑼灣、荃灣、上水及上環等核心地區，全面強化區域服務網絡，拉近與本地客戶的距離，提供更貼心的服務。」「作為港資科技券商No.1^，全球超過800,000用戶，盈立證券十分重視提升用戶的投資體驗，是次開立分行不但提供綜合服務，包括投資諮詢、辦理開戶等，還協助長者及初學者處理開戶流程、學習App使用方法等，藉此深化本地市場，滿足客戶對相關服務的殷切需求。」Neo Lee 續說。(左起︰盈立證券業務拓展總監鄧永麟先生、盈立證券香港市場部總監黃曉霖小姐、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券資產管理兼投研部總監蔣雄先生及盈立證券業務拓展經理林向尊先生)新張期內，前往分行打卡即可獲贈神秘禮品乙份，同時亦可免費享用飲料及手機充電服務，於分行開戶更可額外獲得豐富禮品。為進一步開拓香港市場，盈立證券推出「Trader賬戶」，香港本地客戶專享美港股一世免佣，美股期權0佣優惠。為感謝客戶的支持，uSMART盈立證券亦同時提供多項真全免優惠，不論新客戶或現有客戶，均可享受，絕無取巧，優惠包括：1)IPO 孖展認購0息│現金認購0手續費；2)>100隻港股ETF 0佣0平台費 (當中包括近期投資者熱愛的高息股ETF、虛擬資產相關ETF及指數ETF等)；3)月供美股、港股0佣0平台費0存倉費及免代收股息稅以上優惠旨在滿足短線、中線及長線投資策略，讓持有uSMART盈立證券賬戶的客戶均能受惠。Neo Lee在開幕禮上透露，集團正積極增聘人手，擴充香港及新加坡團隊，以支持及推進業務發展，提高本地市場競爭力；而集團旗下的美國辦公室亦正式進駐至世界金融中心-紐約曼哈頓城中心，並將專注於對接對沖基金、家族辦公室及擬赴美上市企業，提供機構經紀、資產配置及投行諮詢等專業服務，鞏固全球金融科技券商領域的領先地位。展望未來，uSMART盈立證券秉持以客為本的理念，為更多本地投資者提供星級投資體驗及優質線下服務，同時亦致力推動金融服務的創新與升級，為全球客戶創造更多價值。^「港資科技券商No.1」是取自捷利金融雲截至2025年5月為止連續超過一年數據， uSMART 盈立證券為香港本地港資互聯網券商月成交總額排行第1。 優惠受條件及細則約束關於uSMART盈立證券：由周大福控股戰略入股的盈立證券是一間領先科技港資券商，成立於2018年，7年來憑藉卓越的戰略規劃和創新能力，致力於將科技與金融深度融合，業務範圍涵蓋證券、資產管理、財富管理等領域，為全球投資者獨家研發了金融證券交易平台uSMART HK APP和uSMART SG APP，分別由盈立證券（香港）和盈立證券（新加坡）提供服務。集團APP支持港股、美股、A股（滬深港通）、新加坡股票、日本股票、英國股票、美股期權、ETF、基金、債券、資管、結構化票據、期貨、加密貨幣、貴金屬、黃金和外匯等多元化的投資交易服務，此外更為超高淨值個人與家族、企業提供度身訂制服務，打造全方位綜合性資產管理解決方案。詳情可瀏覽https://hk.usmartglobal.com/傳媒查詢：黃曉霖Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 亞太商訊 via SeaPRwire.com.
康哲藥業（867.HK，8A8.SG）上半年營收淨利雙升 戰略轉型跑出增長新動能
深圳，2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 8月18日，康哲藥業發佈2025年中期業績，公司營收和利潤同比均實現增長，戰略轉型成效初顯。報告期內，公司實現營業收入約40.0億元（人民幣，下同），同比增長10.8%。若全按藥品銷售收入計算則營收約46.7億元，同比增長8.9%。實現淨利潤約9.3億元，同比增長3.1%。具體來看，康哲藥業已走出國採陰霾，業績將回歸持續上升軌道。公司主要非國採獨家/品牌產品及創新產品全按藥品銷售收入合計約29.0億元，同比增長20.6%，占總收入比重升至62.1%。公司獨家/品牌產品、創新產品競爭格局良好、增長可預期性強，目前已成為拉動業績向上的主力軍。根據業績公告，公司自2018年起擘畫「新康哲」轉型藍圖，以「產品創新、商業革新、國際拓展」三大戰略為支柱，構建可持續的第二增長曲線。行至2025年上半年，良好的經營業績及創新成果持續落地，證實戰略升級已逐步兌現為硬核戰果。「新產品」戰略推動創新價值兌現 夯實增長後勁立於公司三大戰略之首的「產品創新」戰略，依託「海外授權+國內合作+自主研發」三維創新機制，持續注入高價值短、中、長期管線，成為驅動增長的重要引擎。目前，創新戰略已進入持續收穫期，新產品正不斷釋放商業與臨床價值。截至目前，公司已有5款創新藥成功於中國實現商業化；2025年內，蘆可替尼乳膏和德昔度司他片兩款創新產品亦有望獲批上市。蘆可替尼乳膏是美國FDA以及歐洲EMA批准的首個、也是唯一一個局部JAK抑制劑非節段型白癜風複色產品，有望成為中國獲批上市的首款白癜風治療藥物，將填補市場空白，為中國白癜風患者帶來新希望。此外，阿爾茨海默病新藥ZUNVEYL的中國上市申請(NDA)亦已於今年7月獲受理；消費醫療產品注射用聚左旋乳酸微球填充劑已獲得上市批准，進一步豐富公司多元化產品矩陣。在研創新管線中，已有多款重磅候選藥物進入中國後期臨床開發階段，預計將在未來1-3年內陸續進入商業化，形成持續放量的新動力。其中，合作產品注射用Y-3已完成中國III期臨床，該產品為原創單分子1類新藥，亦為全球唯一進入臨床研究的非肽類PSD95/nNOS解偶聯劑，並有望成為首個治療缺血性卒中並預防卒中後抑鬱焦慮的雙功能腦細胞保護藥物。另一個口服小分子1類新藥ABP-671（URAT1抑制劑）用於治療痛風及高尿酸血症，目前其中國IIb/III期臨床正有序推進中。相較現有主流藥物，該產品有潛力以更低劑量將尿酸降低至更低水平，並具有溶解痛風石的能力，有望為患者提供療效更優、安全性更高的治療選擇。康哲藥業亦持續增厚創新儲備，不斷夯實全鏈條創新實力，以實現創新產品分階段、源源不斷獲批上市。2025上半年，公司新增ZUNVEYL、MG-K10（長效抗IL-4Rα人源化單抗注射液）兩款合作開發創新產品。截至目前，公司累計佈局約40款差異化創新管線，其中約20項為自主研發項目。同步推進「新模式」、「新地域」戰略 拓展多維增量空間根據業績公告，康哲藥業持續推進「新模式-商業革新」戰略，以多元生態鍛造抗週期韌性；並堅定執行「新地域-國際拓展」戰略，以產業國際化出海模式構建多維增長格局。在商業革新戰略下，公司持續聚焦專科領域，同時拓展新零售、新媒體渠道，構建「院內+院外」、「線上+線下」全覆蓋的營銷推廣體系，並持續強化消費醫療產品佈局。公司皮膚健康業務「德鎂醫藥」已在這一具消費屬性的賽道嶄露頭角，自2021年獨立運營以來，已實現皮膚疾病領域適應症覆蓋廣度、皮膚處方藥收入規模的雙重領先，將通過介紹上市、實物分派方式，擬分拆於香港聯交所主板獨立上市，進一步釋放其獨立價值與高成長潛力。國際化方面，2025年7月15日，公司以介紹方式成功於新加坡交易所完成第二上市，「產業國際化」戰略邁入新里程。以新加坡為樞紐，公司構建起覆蓋「研-產-銷」的新興市場全鏈條業務體系。截至目前，商業化平台公司Rxilient已在東南亞、中東、港澳台等地區累計提交近20款藥品和器械註冊申請，涵蓋皮膚科、眼科、腫瘤、自免、中樞神經等領域。蘆可替尼乳膏（白癜風適應症）已在澳門、香港獲批，並已遞交新加坡、台灣註冊申請；靜脈注射用特瑞普利單抗（首個被中國NMPA及美國FDA批准上市的國產抗PD-1單抗藥物）已提交馬來西亞等五國註冊申請；替瑞奇珠單抗注射液、蔗糖羥基氧化鐵咀嚼片亦在香港獲批。同時，公司持股45.0%的聯營CDMO生產工廠PharmaGend，目前已具備片劑、膠囊等口服固體製劑年產10億片的能力，並獲得新加坡HSA頒發的生產許可證、美國FDA cGMP認證及瑞士QP審計通過。PharmaGend鼻噴劑、乳膏、注射劑等新產線的建設正穩步推進中，為國際市場提供高標準生產交付能力。展望未來，「新康哲」增長邏輯有望加速兌現，盈利能力與業績韌性將同步提升。公司正構建以差異化創新為核心、多元生態協同驅動、國際化佈局支撐的增長體系，為高質量發展打開長期空間，為全球患者提供高品質醫藥產品和服務，為股東帶來可持續回報。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平台型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力，其中皮膚健康業務已成爲該細分領域的龍頭企業，帶來專科規模效率。同時，康哲藥業持續深化東南亞及中東區域業務發展，助力高質量持續健康發展。康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com.
Champion REIT Announces 2025 Interim Results
- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.
Champion REIT Announces 2025 Interim Results
- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.
Champion REIT Announces 2025 Interim Results
- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.
uSMART Group Accelerates Expansion with 12 New Branches
HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
uSMART Group Accelerates Expansion with 12 New Branches
HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
uSMART Group Accelerates Expansion with 12 New Branches
HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.
Hitachi High-Tech and NOF Metal Coatings use materials informatics to improve the efficiency and sophistication of research and development work
TOKYO, August 19th, 2025 - (JCN Newswire via SeaPRwire.com) - Hitachi High-Tech ("Hitachi High-Tech") is providing its MI Solutions using Materials Informatics ("MI") to the NOF Metal Coatings Group ("NOF"). We are working together to explore ways to improve the efficiency and sophistication of research and development operations. This has led to a more than 50% reduction in costs related to the number of experiments and time required, as well as to the discovery of new ideas that were difficult to achieve by our own know-how alone, thereby contributing to improved efficiency and sophistication in our research and development work.Background and OverviewNOF's high-performance thin layer coating technology is used to improve the durability and functionality of metals. NOF mainly develops and manufactures rust-proof materials that protect metals from rust, and provides them to a wide range of industries including the automotive and aviation industries, both in Japan and overseas. In recent years, there have been more and more demands regarding new value and product development, such as product safety and consideration for the environment. In addition, we have previously relied on the experience of experienced engineers for the advancement of research and development work, but as more experienced engineers are getting older and the number of young engineers increasing, we wanted to transform conventional methods and develop data-driven technologies in order to speed up our research and development process.Under these circumstances, Hitachi High-Tech provided its MI Solutions to NOF, aiming to accurately understand the current situation and identify key issues through repeated dialog, then provide continued support in solving these issues through MI and data analysis. As a result, NOF has managed to reduce the number and duration of experiments by more than 50% for research and development work of specific topics, compared to before using MI. They have also be enable to develop new ideas that could not be imagined using traditional methods, and have contributed to the development of more sophisticated and efficient products.The Specific Solution Offered by Hitachi High-TechMI, the core technology of Hitachi High-Tech's MI Solution, uses AI technology to predict physical properties and derive optimal conditions for manufacturing conditions and material blending ratios based on accumulated experimental data. Consulting support using MI and generative AI embodies the Lumada*1 3.0, which uses the Hitachi Group's domain knowledge and AI technology to transform data into value and resolve issues for customers and society.*1 Lumada: A collective term for solutions, services, and technologies based on Hitachi's advanced digital technologies for creating value from customers' data accelerating digital innovation.(1) Provision of a material data analysis environmentThey used Hitachi High-Tech's MI technology to analyze past study data for experimental candidates that can be expected to have the desired properties for development areas such as the anti-rust materials developed by NOF over many years. This led to a more than 50% reduction in costs related to the number of experiments and time required for specific research topics. It also led to new discoveries, which were difficult to achieve with conventional methods, demonstrating the effectiveness of data-driven development and contributing to the advancement of research and development.(2) Consulting support through customer successHitachi High-Tech directly provides customer support by data scientists and other people working on customer success at Hitachi High-Tech. This has enabled NOF to smoothly advance their use of MI even without in-house MI and data analysis experts. Also, by conducting thorough hearings with Hitachi High-Tech personnel, they were able to identify real issues in research and development work and propose appropriate approaches to resolve them, thereby improving efficiency and sophistication.Future OutlookHitachi High-Tech has been providing materials development solutions to a variety of domestic and overseas customers since 2021, focusing on materials and chemical manufacturers. NOF also has group companies overseas, and they are aiming to use MI technology at their overseas offices to further create value globally and increase adoption. The two companies will continue to work together to support the overseas expansion of NOF's use of MI technology, utilizing Hitachi High-Tech's expertise from providing solutions to a large number of customers. In addition, we will continue offering proposals and promoting collaborations aimed at improved efficiency and sophistication, such as further automation of research and development work, through seamless collaboration between MI and data generated from analysis equipment provided by Hitachi High-Tech, and through the use of AI technology and Hitachi Group assets.Going forward, Hitachi High-Tech will continue leveraging our capabilities of global frontline functions, domain knowledge, points of contact and technological capabilities to create solutions and business models that lead to solutions stemming from all forms of social issues, and to contribute to market growth in the industrial and social infrastructure fields.Related LinksMI Case study (NOF Metal Coatings)About MI SolutionsAbout Hitachi High-TechHitachi High-Tech provides cutting-edge technologies, products and services to society and customers with its corporate vision of "Changing the World and Future with the Power of Knowledge" to contribute to a sustainable global environment, healthy, safe and secure lives, and the sustained development of science and industry. We manufacture and sell clinical analyzers, biotechnology products and radiation therapy systems in the healthcare field, semiconductor manufacturing and inspection equipment in the semiconductor field, as well as analytical systems and electron microscopes used in environmental fields and materials research. We are also engaged in a wide range of business areas globally, providing high added-value solutions in battery, communication infrastructure, railway inspection, digital and other industrial and social infrastructure fields. We provide solutions through a deeper understanding of the issues facing society and our customers to contribute to realizing a sustainable society. The company's consolidated revenues for FY2024 were approx. JPY 756.5 billion. For further information, visit https://www.hitachi-hightech.com/global/en/Business ContactInformatics Promotion Dept.,Industrial & Social Infrastructure Business Group,Hitachi High-Tech CorporationInformatics.aj@hitachi-hightech.com Copyright 2025 JCN Newswire via SeaPRwire.com.